RIDGEFIELD, Conn., March 14, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI), today announced that Pradaxa® (dabigatran etexilate mesylate) capsules has received preferred Tier 2 formulary status with CVS Caremark (Commercial Preferred Drug List) and Medco (Commercial Preferred and Part D Drug Lists), two of the largest pharmacy benefit managers covering more than 100 million Americans.(1) The U.S. Food and Drug Administration (FDA) approved PRADAXA in October 2010 to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).(2)
Five months after FDA approval, PRADAXA is now available at the lowest branded co-pay level on formularies that insure about 35 percent of NVAF patients.(1) For those patients who may not otherwise be able to afford treatment, BIPI offers patient assistance programs to help provide coverage for the costs of their medications.
In the pivotal RE-LY trial, PRADAXA 150mg capsules taken twice daily reduced the incidence of stroke and systemic embolism by 35 percent beyond the reduction achieved with warfarin(2), which was dosed to a target international normalized ratio (INR) of 2.0 to 3.0.(2) The effects of PRADAXA compared to warfarin were more apparent in patients with lower levels of INR control.(2)
"These formulary additions will offer non-valvular atrial fibrillation patients increased access to PRADAXA, including its demonstrated ability to significantly reduce the risk of stroke over warfarin in this patient population," said Wa'el Hashad, vice president, cardiovascular and metabolic disorders marketing, Boehringer Ingelheim Pharmaceuticals, Inc. "We look forward to a long relationship with CVS Caremark and Medco, and are committed to working with other pharmacy benefit managers as well as offering our own programs to help make PRADAXA available to patients with non-valvular atrial fibrillation."
PRADAXA is the only FDA-approved treat